Literature DB >> 1672178

Topical calcipotriol treatment in advanced breast cancer.

M Bower1, K W Colston, R C Stein, A Hedley, J C Gazet, H T Ford, R C Combes.   

Abstract

19 patients with locally advanced or cutaneous metastatic breast cancer were treated with the topical vitamin D analogue calcipotriol 100 micrograms daily. 14 patients completed 6 weeks' treatment; 3 showed a 50% reduction in the bidimensional diameter of treated lesions and 1 other patient showed a minimal response. 2 patients became hypercalcaemic during treatment. In all patients who responded the tumours contained receptors for 1,25-dihydroxyvitamin D3, shown by immunocytochemistry.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1672178     DOI： 10.1016/0140-6736(91)90280-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  16 in total

1.  Effects of vitamin D and retinoic acid on human glioblastoma cell lines.

Authors:  L Magrassi; G Butti; S Pezzotta; L Infuso; G Milanesi
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

Review 2.  Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects.

Authors:  Sylvia Christakos; Puneet Dhawan; Annemieke Verstuyf; Lieve Verlinden; Geert Carmeliet
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 3.  Vitamin D, disease and therapeutic opportunities.

Authors:  Lori A Plum; Hector F DeLuca
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

4.  Hypercalcaemia associated with calcipotriol (Dovonex) treatment.

Authors:  K A Hardman; D A Heath; H M Nelson
Journal:  BMJ       Date:  1993-04-03

5.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.

Authors:  C M Hansen; T L Frandsen; N Brünner; L Binderup
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

6.  Vitamin D receptors in breast cancer cells.

Authors:  R R Buras; L M Schumaker; F Davoodi; R V Brenner; M Shabahang; R J Nauta; S R Evans
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.

Authors:  G J Rustin; T G Quinnell; J Johnson; H Clarke; A E Nelstrop; W Bollag
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  MART-10, a New Generation of Vitamin D Analog, Is More Potent than 1α,25-Dihydroxyvitamin D(3) in Inhibiting Cell Proliferation and Inducing Apoptosis in ER+ MCF-7 Breast Cancer Cells.

Authors:  Kun-Chun Chiang; Chun-Nan Yeh; Shin-Cheh Chen; Shih-Che Shen; Jun-Te Hsu; Ta-Sen Yeh; Jong-Hwei S Pang; Li-Jen Su; Masashi Takano; Atsushi Kittaka; Horng-Heng Juang; Tai C Chen
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-11       Impact factor: 2.629

9.  Transcriptional effects of 1,25 dihydroxyvitamin D(3) physiological and supra-physiological concentrations in breast cancer organotypic culture.

Authors:  Cintia Milani; Maria Lucia Hirata Katayama; Eduardo Carneiro de Lyra; JoEllen Welsh; Laura Tojeiro Campos; M Mitzi Brentani; Maria do Socorro Maciel; Rosimeire Aparecida Roela; Paulo Roberto del Valle; João Carlos Guedes Sampaio Góes; Suely Nonogaki; Rodrigo Esaki Tamura; Maria Aparecida Azevedo Koike Folgueira
Journal:  BMC Cancer       Date:  2013-03-15       Impact factor: 4.430

10.  A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.

Authors:  T Gulliford; J English; K W Colston; P Menday; S Moller; R C Coombes
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.